WO2018232174A2 - Compositions and methods for treating flavivirus infections - Google Patents
Compositions and methods for treating flavivirus infections Download PDFInfo
- Publication number
- WO2018232174A2 WO2018232174A2 PCT/US2018/037629 US2018037629W WO2018232174A2 WO 2018232174 A2 WO2018232174 A2 WO 2018232174A2 US 2018037629 W US2018037629 W US 2018037629W WO 2018232174 A2 WO2018232174 A2 WO 2018232174A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- ritonavir
- antibiotic compound
- novobiocin
- antiviral
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 52
- 238000000034 method Methods 0.000 title claims description 20
- 206010054261 Flavivirus infection Diseases 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 60
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 59
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 claims abstract description 47
- 229960002950 novobiocin Drugs 0.000 claims abstract description 47
- 230000003115 biocidal effect Effects 0.000 claims abstract description 46
- OFFWOVJBSQMVPI-RMLGOCCBSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O.N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 OFFWOVJBSQMVPI-RMLGOCCBSA-N 0.000 claims abstract description 41
- 241000710842 Japanese encephalitis virus Species 0.000 claims abstract description 23
- 241000710886 West Nile virus Species 0.000 claims abstract description 23
- 241000725619 Dengue virus Species 0.000 claims abstract description 22
- 241000710772 Yellow fever virus Species 0.000 claims abstract description 20
- 229940051021 yellow-fever virus Drugs 0.000 claims abstract description 20
- 230000002195 synergetic effect Effects 0.000 claims abstract description 13
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 claims abstract 15
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 38
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 claims description 38
- 238000009472 formulation Methods 0.000 claims description 32
- 241000710831 Flavivirus Species 0.000 claims description 24
- 241000700605 Viruses Species 0.000 claims description 24
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 20
- 229960000329 ribavirin Drugs 0.000 claims description 20
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 19
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims description 19
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 19
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 19
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 19
- 229960003805 amantadine Drugs 0.000 claims description 19
- 229960003405 ciprofloxacin Drugs 0.000 claims description 19
- 229960003722 doxycycline Drugs 0.000 claims description 19
- 229960004502 levodopa Drugs 0.000 claims description 19
- 229960004023 minocycline Drugs 0.000 claims description 19
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 18
- 229960000311 ritonavir Drugs 0.000 claims description 18
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 18
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4s,4as,5ar,12ar)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 claims description 17
- 241000711549 Hepacivirus C Species 0.000 claims description 17
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 17
- 239000004098 Tetracycline Substances 0.000 claims description 17
- 208000015181 infectious disease Diseases 0.000 claims description 17
- 229960003376 levofloxacin Drugs 0.000 claims description 17
- 229960003702 moxifloxacin Drugs 0.000 claims description 17
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims description 17
- 229960002180 tetracycline Drugs 0.000 claims description 17
- 229930101283 tetracycline Natural products 0.000 claims description 17
- 235000019364 tetracycline Nutrition 0.000 claims description 17
- 150000003522 tetracyclines Chemical class 0.000 claims description 17
- 229960004089 tigecycline Drugs 0.000 claims description 17
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 229960004525 lopinavir Drugs 0.000 claims description 6
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims description 5
- 208000004576 Flaviviridae Infections Diseases 0.000 claims description 5
- 201000005807 Japanese encephalitis Diseases 0.000 claims description 5
- 229940120922 lopinavir and ritonavir Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 241000710781 Flaviviridae Species 0.000 abstract description 10
- YJQPYGGHQPGBLI-KGSXXDOSSA-M novobiocin(1-) Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C([O-])=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-M 0.000 description 33
- 229940113983 lopinavir / ritonavir Drugs 0.000 description 16
- 229940079593 drug Drugs 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 210000003501 vero cell Anatomy 0.000 description 9
- 239000002609 medium Substances 0.000 description 8
- 230000000120 cytopathologic effect Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 5
- 239000000890 drug combination Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000013553 cell monolayer Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 2
- 108010016076 Octreotide Proteins 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 2
- 229960003946 selegiline Drugs 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960001967 tacrolimus Drugs 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 description 1
- QWZHDKGQKYEBKK-UHFFFAOYSA-N 3-aminochromen-2-one Chemical compound C1=CC=C2OC(=O)C(N)=CC2=C1 QWZHDKGQKYEBKK-UHFFFAOYSA-N 0.000 description 1
- PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 229940122440 HIV protease inhibitor Drugs 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- -1 NSP2A Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 101710144128 Non-structural protein 2 Proteins 0.000 description 1
- 101710144111 Non-structural protein 3 Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100022648 Reticulon-2 Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102100021798 SH2 domain-containing protein 3C Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241001454746 Streptomyces niveus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960001280 amantadine hydrochloride Drugs 0.000 description 1
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000941 anti-staphylcoccal effect Effects 0.000 description 1
- 238000002832 anti-viral assay Methods 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Chemical class 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 229960002845 desmopressin acetate Drugs 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004082 doxycycline hydrochloride Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960004781 novobiocin sodium Drugs 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 229960001494 octreotide acetate Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the field of the invention is compositions and methods for treating viral infections, more specifically dengue virus, Japanese encephalitis virus, West Nile virus, yellow fever virus, and hepatitis C virus.
- Flaviviridae are a family of over 100 species of single stranded RNA viruses, members of which are known to cause animal and human disease. They spread primarily by arthropod vectors (e.g. mosquitoes, ticks, etc.) Diseases caused by flaviviridae include hepatitis, encephalitis, and hemorrhagic fever/syndromes.
- the viral genome encodes a single polyprotein that is processed by viral and host proteases to provide structural and non-structural proteins.
- NS non-structural
- RNA or polyprotein processing are highly conserved. Such highly conserved regions are useful in identification and phylogenetic analysis by nucleic acid amplification methods.
- inventive subject matter provides compositions and methods for treatment of flaviviradae , using novobiocin or lopinavir-ritonavir in combination with an additional antibiotic or antiviral compound.
- One embodiment of the inventive concept is a composition for the treatment of flaviviridae infection that includes novobiocin (for example, at from about 1 ⁇ to about 1 mM) and a secondary antiviral or antibiotic compound, where the novobiocin and the secondary antiviral or antibiotic compound exhibit a synergistic effect in inhibiting a virus of the flavivirus family.
- Suitable secondary antiviral or antibiotic compound include ribavarin, ritonavir, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, doxycycline, amantadine, levodopa, and/or isatin.
- Viruses susceptible to such a drug combination include dengue virus, Japanese encephalitis, West Nile virus, yellow fever virus, and/or hepatitis C virus.
- compositions for the treatment of flaviviridae infection that includes lopinavir-ritonavir (for example, at from about 1 ⁇ to about 1 mM) and a secondary antiviral or antibiotic compound, where the lopinavir-ritonavir and the secondary antiviral or antibiotic compound exhibit a synergistic effect in inhibiting a virus of the flavivirus family.
- Suitable secondary antiviral or antibiotic compound include ribavarin, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, doxycycline, amantadine, levodopa, and/or isatin.
- Viruses susceptible to such a drug combination include dengue virus, Japanese encephalitis, West Nile virus, yellow fever virus, and/or hepatitis C virus.
- Another embodiment of the inventive concept is a method of treating an infection caused by a member of the flavivirus family (such as dengue virus, Japanese encephalitis virus, West Nile virus, yellow fever virus, and hepatitis C virus), by providing to a person in need of treatment a formulation that includes novobiocin.
- the formulation also includes a secondary antiviral or antibiotic compound, such as ribavarin, ritonavir, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, and
- Such formulation can provide novobiocin in a concentration range of about 1 ⁇ to about 1 mM.
- Another embodiment of the inventive concept is a method of treating an infection caused by a member of the flavivirus family (such as dengue virus, Japanese encephalitis virus, West Nile virus, yellow fever virus, and hepatitis C virus), by providing to a person in need of treatment a formulation that includes lopinavir-ritonavir.
- the formulation also includes a secondary antiviral or antibiotic compound, such as ribavarin, ritonavir, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, and doxycycline, amantadine, levodopa, and/or isatin.
- a secondary antiviral or antibiotic compound such as ribavarin, ritonavir, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, and doxycycline, am
- kits for treating an infection caused by a member of the flavivirus family such as dengue virus, Japanese encephalitis virus, West Nile virus, yellow fever virus, and hepatitis C virus.
- the kit includes novobiocin and a secondary antiviral or antibiotic compound (such as ribavarin, ritonavir, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, and doxycycline, amantadine, levodopa, and/or isatin).
- a secondary antiviral or antibiotic compound such as ribavarin, ritonavir, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, and doxycycline, amantadine, levodopa, and/or isatin.
- the novobiocin and the secondary antiviral or antibiotic compound are provided as a single formulation; in other embodiments they are provided as separate formulations.
- the kit is formulated to provide novobiocin in a concentration range of about 1 ⁇ to about 1 mM. Such a kit can include instructions for use, such as a dosing schedule effective in treating the infection.
- Another embodiment of the inventive concept is a kit for treating an infection caused by a member of the flavivirus family (such as dengue virus, Japanese encephalitis virus, West Nile virus, yellow fever virus, and hepatitis C virus).
- the kit includes lopinavir, ritonavir, and a secondary antiviral or antibiotic compound (such as ribavarin, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, and doxycycline, amantadine, levodopa, and/or isatin).
- a secondary antiviral or antibiotic compound such as ribavarin, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, and doxycycline, amantadine, levodopa, and/or isatin.
- the lopinavir, ritonavir, and the secondary antiviral or antibiotic compound are provided as a single formulation; in other embodiments they are provided as separate formulations.
- the kit is formulated to provide lopinavir-ritonavir in a
- kits of one of claims 26 to 29, wherein the secondary antiviral or antibiotic compound is selected from the group consisting of ribavarin, ritonavir, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, and doxycycline, amantadine, levodopa, and isatin.
- FIG. 1 Structure of novobiocin.
- FIG. 2 Structure of lopinavir.
- FIG. 3 Structure of ritonavir.
- inventive subject matter is directed to compositions and methods that are useful in preventing and/or treating Japanese encephalitis, West Nile virus, hepatitis C virus, Dengue virus, and/or Yellow Fever virus infections.
- novobiocin was identified as having this activity, as has lopinavir/ritonavir.
- Novobiocin is an aminocoumarin antibiotic produced by Streptomyces niveus, and has been known since the 1950's as an antibacterial drug.
- Lopinavir/ritonavir (sold commercially in combination as KaletraTM) is a drug combination used as a specific HIV protease inhibitor, and is currently approved for use in the treatment and prevention of HIV infections/AIDS.
- the structures of lopinavir and ritonavir are shown in FIGs. 2 and 3, respectively. Although this drug combination produces some notable side effects (e.g. fatigue, headache, nausea, diarrhea) it is considered safe and is approved for use in pregnancy.
- inventive subject matter provides many example embodiments of the inventive subject matter. Although each embodiment represents a single combination of inventive elements, the inventive subject matter is considered to include all possible combinations of the disclosed elements. Thus if one embodiment comprises elements A, B, and C, and a second embodiment comprises elements B and D, then the inventive subject matter is also considered to include other remaining combinations of A, B, C, or D, even if not explicitly disclosed.
- novobiocin and/or lopinavir/ritonavir is provided on a treatment schedule that is effective in treating an infection caused by a member of the flaviviridae family, particularly dengue virus, Japanese encephalitis virus, West Nile virus, yellow fever virus, and hepatitis C virus.
- Novobiocin and/or lopinavir/ritonavir can be provided as an oral formulation (e.g. liquid suspension or solution, pill, tablet, capsule, powder, gel, etc.), but can also be provided as an injectable or infusible formulation, a topical formulation, an inhaled formulation, and/or a formulation suitable for mucosal (e.g.
- novobiocin and/or lopinavir/ritonavir can be provided in a sustained-release formulation.
- Suitable treatment schedules can provide novobiocin and/or lopinavir/ritonavir on a daily, 12 hour, 8 hour, 6 hour, 4 hour, or shorter interval.
- novobiocin and/or lopinavir/ritonavir can be provided every 2 days, every 3 days, weekly, every two weeks, monthly, or at longer intervals.
- Such treatment schedules can be provided for as short as two days or for as long as a year or more.
- treatment with novobiocin and/or lopinavir/ritonavir can extend for the remainder of the patient' s life.
- novobiocin and/or lopinavir/ritonavir When used as an antiviral agent against flaviviridae unexpected synergistic effects were found when novobiocin and/or lopinavir/ritonavir was used in combination with other antiviral/antibiotic compounds, including ribavarin, ritonavir, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, doxycycline, amantadine, levodopa, and isatin.
- novobiocin and/or lopinavir/ritonavir is provided in combination with such complementary antiviral/antibiotic agents.
- novobiocin and/or lopinavir/ritonavir and one or more complementary antiviral/antibiotic agents are provided as a single formulation.
- lopinavir/ritonavir and one or more antiviral/antibiotic agents are provided as separate formulations. Such separate formulations can be provided on the same or different treatment schedules.
- novobiocin and/or lopinavir/ritonavir can be provided with additional pharmaceutical compounds that provide symptomatic relief.
- additional pharmaceutical compounds include anti-inflammatory compounds, anti-emetic compounds, pain relieving compounds, and/or fever reducing compounds.
- novobiocin and/or lopinavir/ritonavir can complex with amino acids (e.g. His51) found in highly conserved regions of flaviviridae proteases (e.g. NSP2, NSP2A, NSP3) and/or other nonstructural gene products.
- amino acids e.g. His51
- flaviviridae proteases e.g. NSP2, NSP2A, NSP3
- Such complex formation inhibits protease/protein activity and provides antiviral activity, which is complementary to antiviral activity provided by other antiviral compounds in a synergistic fashion.
- the carboxamine group of novobiocin is at least partially responsible for this activity.
- Virus was amplified by passage in Vero cells (ATCC) cultured in minimum essential medium (MEM) supplemented with 1% fetal bovine serum (FBS, GibcoTM, Life Technologies Corporation, Massachusetts, USA) and 100 units/ml penicillin plus 100 mg/ml streptomycin.
- Working stocks of virus were prepared at 4 x 10 6 tissue culture infectious dose (TCID 5 o)/ml.
- TCID 50 was interpreted as the amount of virus that resulting in CPE in 50% of inoculated wells.
- CPE was determined by examination using inverted light microscopy, and supernatant was collected for virus quantification.
- a 4 1 mixture of serum free MEM and 5 mg/ml MTT solution (prepared in 1 x PBS, filtered) was then added to the wells. The cell monolayers were incubated as above for 4 hours in the absence of light. 10% sodium dodecyl sulfate with 0.01M HC1 was then added the wells, which were subsequently incubated at 37° C in 5% C0 2 overnight.
- Activity was characterized by measuring optical density at 570nm with reference absorbance read at 640nm.
- the half maximal inhibitory concentration (IC 50 ) and CC 50 were calculated using Sigma plot (SPSS) as Excel add-in ED50V10. Drug compounds were selected for combination studies with novobiocin or lopinavir-ritonavir using the CPE inhibition assay and the Loewe additivity index was calculated.
- Virus yield reduction was determined by quantitative reverse transcription-PCR (qRT- PCR) using total nucleic acid extracted from culture supernatants of the Vero cells infected by flaviviridae with different drugs or a dimethyl sulfoxide (DMSO) control at 6 days post- inoculation (dpi), ⁇ -actin gene was used as an internal control.
- qRT- PCR quantitative reverse transcription-PCR
- Plaque reduction was determined by seeding Vero cells at 2 x 10 5 cells/well in 24- well tissue culture plates in MEM (Invitrogen, California, USA) with 10% FBS on the day prior to the assay. After 24 hours of incubation, 20-40 plaque-forming units of the virus were added to the cell monolayer with or without the addition of drug compounds and the plates further incubated for 1 hour at 37° C in 5% C0 2 , after unbound viral particles were removed by aspiration of the media and washing with MEM. The monolayers were then overlaid with media containing 1% low melting agarose (Cambrex Corporation, New Jersey, USA) in MEM and appropriate concentrations of drug compounds and incubated as above for 96 hours. The wells were then fixed with 10% formaldehyde (BDH, Merck, Darmstadt, Germany) overnight.
- novobiocin and lopinavir-ritonavir exhibited antiviral activity against all tested viruses, including DENV serotypes 1 to 4, JEV, WNV, and YFV.
- the CC 50 of novobiocin and lopinavir-ritonavir was 850.5 ⁇ g/ml (1,388.02 ⁇ ) and 30.0 ⁇ g/ml in Vero cells,
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Novobiocin and lopinavir-ritonavir have been found to have significant antiviral activity against a variety of members of the flaviviridae family, including dengue virus, Japanese encephalitis virus, and West Nile virus, and yellow fever virus. Synergistic antiviral effects are found when either novobiocin or lopinavir-ritonavir are used in combination with a variety of other antibiotic and antiviral compounds.
Description
COMPOSITIONS AND METHODS FOR TREATING FLAVIVIRUS INFECTIONS
[0001] This application claims the benefit of United States Provisional Application No.
62/521178, filed on June 16, 2017. These and all other referenced extrinsic materials are incorporated herein by reference in their entirety. Where a definition or use of a term in a reference that is incorporated by reference is inconsistent or contrary to the definition of that term provided herein, the definition of that term provided herein is deemed to be controlling.
Field of the Invention
[0002] [0001] The field of the invention is compositions and methods for treating viral infections, more specifically dengue virus, Japanese encephalitis virus, West Nile virus, yellow fever virus, and hepatitis C virus.
Background
[0003] The background description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.
[0004] Flaviviridae are a family of over 100 species of single stranded RNA viruses, members of which are known to cause animal and human disease. They spread primarily by arthropod vectors (e.g. mosquitoes, ticks, etc.) Diseases caused by flaviviridae include hepatitis, encephalitis, and hemorrhagic fever/syndromes. The viral genome encodes a single polyprotein that is processed by viral and host proteases to provide structural and non-structural proteins. Several of the non-structural ("NS") proteins include portions utilized in RNA or polyprotein processing that are highly conserved. Such highly conserved regions are useful in identification and phylogenetic analysis by nucleic acid amplification methods.
[0005] Treatment options for many diseases associated with flaviviridae are limited. For example current treatment for Japanese encephalitis, which has a case-fatality rate of
approximately 30%, is essentially symptomatic and supportive. Similarly, no specific treatment
is available for West Nile virus, which has become widespread throughout the US with annual case-mortality rates ranging from 3% to 15%. Hepatitis C has been treated with some success using a combination of ribavarin and interferon, however such treatment provided a cure rate of only around 50% and is associated with unpleasant side effects. Highly effective antiviral drugs have recently become available for hepatitis C, however successful treatment is dependent on the genome of the infecting virus and is remarkably expensive (approximately $1,000 USD per pill for a daily treatment regime that extends up to 6 months). Such costs render these drugs essentially inaccessible for treatment of hepatitis C on a public health scale.
[0006] Thus, there is still a need for safe and effective compositions and methods for treatment of flaviviridae infections.
Summary of The Invention
[0007] The inventive subject matter provides compositions and methods for treatment of flaviviradae , using novobiocin or lopinavir-ritonavir in combination with an additional antibiotic or antiviral compound.
[0008] One embodiment of the inventive concept is a composition for the treatment of flaviviridae infection that includes novobiocin (for example, at from about 1 μΜ to about 1 mM) and a secondary antiviral or antibiotic compound, where the novobiocin and the secondary antiviral or antibiotic compound exhibit a synergistic effect in inhibiting a virus of the flavivirus family. Suitable secondary antiviral or antibiotic compound include ribavarin, ritonavir, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, doxycycline, amantadine, levodopa, and/or isatin. Viruses susceptible to such a drug combination include dengue virus, Japanese encephalitis, West Nile virus, yellow fever virus, and/or hepatitis C virus.
[0009] Another embodiment of the inventive concept is a composition for the treatment of flaviviridae infection that includes lopinavir-ritonavir (for example, at from about 1 μΜ to about 1 mM) and a secondary antiviral or antibiotic compound, where the lopinavir-ritonavir and the secondary antiviral or antibiotic compound exhibit a synergistic effect in inhibiting a virus of the flavivirus family. Suitable secondary antiviral or antibiotic compound include ribavarin, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, doxycycline,
amantadine, levodopa, and/or isatin. Viruses susceptible to such a drug combination include dengue virus, Japanese encephalitis, West Nile virus, yellow fever virus, and/or hepatitis C virus.
[0010] Another embodiment of the inventive concept is a method of treating an infection caused by a member of the flavivirus family (such as dengue virus, Japanese encephalitis virus, West Nile virus, yellow fever virus, and hepatitis C virus), by providing to a person in need of treatment a formulation that includes novobiocin. In some of such embodiments the formulation also includes a secondary antiviral or antibiotic compound, such as ribavarin, ritonavir, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, and
doxycycline, amantadine, levodopa, and/or isatin. Such formulation can provide novobiocin in a concentration range of about 1 μΜ to about 1 mM.
[0011] Another embodiment of the inventive concept is a method of treating an infection caused by a member of the flavivirus family (such as dengue virus, Japanese encephalitis virus, West Nile virus, yellow fever virus, and hepatitis C virus), by providing to a person in need of treatment a formulation that includes lopinavir-ritonavir. In some of such embodiments the formulation also includes a secondary antiviral or antibiotic compound, such as ribavarin, ritonavir, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, and doxycycline, amantadine, levodopa, and/or isatin. Such formulation can provide lopinavir- ritonavir in a concentration range of about 1 μΜ to about 1 mM.
[0012] Another embodiment of the inventive concept is a kit for treating an infection caused by a member of the flavivirus family (such as dengue virus, Japanese encephalitis virus, West Nile virus, yellow fever virus, and hepatitis C virus). The kit includes novobiocin and a secondary antiviral or antibiotic compound (such as ribavarin, ritonavir, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, and doxycycline, amantadine, levodopa, and/or isatin). In some embodiments the novobiocin and the secondary antiviral or antibiotic compound are provided as a single formulation; in other embodiments they are provided as separate formulations. In some embodiments the kit is formulated to provide novobiocin in a concentration range of about 1 μΜ to about 1 mM. Such a kit can include instructions for use, such as a dosing schedule effective in treating the infection.
[0013] Another embodiment of the inventive concept is a kit for treating an infection caused by a member of the flavivirus family (such as dengue virus, Japanese encephalitis virus, West Nile virus, yellow fever virus, and hepatitis C virus). The kit includes lopinavir, ritonavir, and a secondary antiviral or antibiotic compound (such as ribavarin, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, and doxycycline, amantadine, levodopa, and/or isatin). In some embodiments the lopinavir, ritonavir, and the secondary antiviral or antibiotic compound are provided as a single formulation; in other embodiments they are provided as separate formulations. In some embodiments the kit is formulated to provide lopinavir-ritonavir in a concentration range of about 1 μΜ to about 1 mM. Such a kit can include instructions for use, such as a dosing schedule effective in treating the infection.
[0014] 30. The kit of one of claims 26 to 29, wherein the secondary antiviral or antibiotic compound is selected from the group consisting of ribavarin, ritonavir, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, and doxycycline, amantadine, levodopa, and isatin.
[0015] Various objects, features, aspects and advantages of the inventive subject matter will become more apparent from the following detailed description of preferred embodiments, along with the accompanying drawing figures in which like numerals represent like components.
Brief Description of The Drawings
[0016] FIG. 1: Structure of novobiocin.
[0017] FIG. 2: Structure of lopinavir.
[0018] FIG. 3: Structure of ritonavir.
Detailed Description
[0019] The following description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.
[0020] The inventive subject matter is directed to compositions and methods that are useful in preventing and/or treating Japanese encephalitis, West Nile virus, hepatitis C virus, Dengue virus, and/or Yellow Fever virus infections. Surprisingly, novobiocin was identified as having this activity, as has lopinavir/ritonavir. Novobiocin is an aminocoumarin antibiotic produced by Streptomyces niveus, and has been known since the 1950's as an antibacterial drug. It is licensed for clinical use as an oral formulation under the trade name Albamycin™ and has been used as an antistaphylococcal agent effective against methicillin-resistant streptococcus. When used as an antibiotic it is well tolerated, with few and minor side effects. The structure of novobiocin is shown in FIG. 1. Lopinavir/ritonavir (sold commercially in combination as Kaletra™) is a drug combination used as a specific HIV protease inhibitor, and is currently approved for use in the treatment and prevention of HIV infections/AIDS. The structures of lopinavir and ritonavir are shown in FIGs. 2 and 3, respectively. Although this drug combination produces some notable side effects (e.g. fatigue, headache, nausea, diarrhea) it is considered safe and is approved for use in pregnancy.
[0021] Functional testing has shown that novobiocin and/or lopinavir/ritonavir is effective in inhibiting flaviviridae in culture at μΜ concentrations. Surprisingly, synergistic (i.e. greater than additive) effects are found when used in combination with known antiviral compounds and/or antibiotics such as ribavarin, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, and doxycycline.
[0022] Various objects, features, aspects and advantages of the inventive subject matter will become more apparent from the following detailed description of preferred embodiments, along with the accompanying drawing figures in which like numerals represent like components.
[0023] One should appreciate that the disclosed techniques provide many advantageous technical effects including provision of antiviral activity using a well tolerated, regulatory agency approved compound having a known safety profile, and provision of synergistic effects when such a compound is used in combination with antiviral compounds in current use.
[0024] The following discussion provides many example embodiments of the inventive subject matter. Although each embodiment represents a single combination of inventive elements, the inventive subject matter is considered to include all possible combinations of the disclosed
elements. Thus if one embodiment comprises elements A, B, and C, and a second embodiment comprises elements B and D, then the inventive subject matter is also considered to include other remaining combinations of A, B, C, or D, even if not explicitly disclosed.
[0025] Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member can be referred to and claimed individually or in any combination with other members of the group or other elements found herein. One or more members of a group can be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the
specification is herein deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.
[0026] In some embodiments of the inventive concept, novobiocin and/or lopinavir/ritonavir is provided on a treatment schedule that is effective in treating an infection caused by a member of the flaviviridae family, particularly dengue virus, Japanese encephalitis virus, West Nile virus, yellow fever virus, and hepatitis C virus. Novobiocin and/or lopinavir/ritonavir can be provided as an oral formulation (e.g. liquid suspension or solution, pill, tablet, capsule, powder, gel, etc.), but can also be provided as an injectable or infusible formulation, a topical formulation, an inhaled formulation, and/or a formulation suitable for mucosal (e.g. nasal, vaginal, rectal, etc.) administration. Such formulations can provide novobiocin and/or lopinavir/ritonavir in amounts ranging from 1 mg to 10 g, and can include additives such as bulking agents, flavorants, excipients, vehicles, transport enhancers, and/or stabilizing agents. In some embodiments novobiocin and/or lopinavir/ritonavir can be provided in a sustained-release formulation.
[0027] Suitable treatment schedules can provide novobiocin and/or lopinavir/ritonavir on a daily, 12 hour, 8 hour, 6 hour, 4 hour, or shorter interval. Alternatively, in some embodiments novobiocin and/or lopinavir/ritonavir can be provided every 2 days, every 3 days, weekly, every two weeks, monthly, or at longer intervals. Such treatment schedules can be provided for as short as two days or for as long as a year or more. In some embodiments treatment with novobiocin and/or lopinavir/ritonavir can extend for the remainder of the patient' s life.
[0028] When used as an antiviral agent against flaviviridae unexpected synergistic effects were found when novobiocin and/or lopinavir/ritonavir was used in combination with other
antiviral/antibiotic compounds, including ribavarin, ritonavir, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, doxycycline, amantadine, levodopa, and isatin. As such, in some embodiments novobiocin and/or lopinavir/ritonavir is provided in combination with such complementary antiviral/antibiotic agents. In such embodiments novobiocin and/or lopinavir/ritonavir and one or more complementary antiviral/antibiotic agents are provided as a single formulation. In other embodiments, novobiocin and/or
lopinavir/ritonavir and one or more antiviral/antibiotic agents are provided as separate formulations. Such separate formulations can be provided on the same or different treatment schedules.
[0029] In still other embodiments, novobiocin and/or lopinavir/ritonavir can be provided with additional pharmaceutical compounds that provide symptomatic relief. Suitable additional pharmaceutical compounds include anti-inflammatory compounds, anti-emetic compounds, pain relieving compounds, and/or fever reducing compounds.
[0030] Without wishing to be bound by theory, the Applicants believe that novobiocin and/or lopinavir/ritonavir can complex with amino acids (e.g. His51) found in highly conserved regions of flaviviridae proteases (e.g. NSP2, NSP2A, NSP3) and/or other nonstructural gene products. Such complex formation inhibits protease/protein activity and provides antiviral activity, which is complementary to antiviral activity provided by other antiviral compounds in a synergistic fashion. Without wishing to be bound by theory, Applicants believe that the carboxamine group of novobiocin is at least partially responsible for this activity.
Examples
Viruses and cell lines
[0031] Clinical isolates of dengue virus (DENV) serotypes 1 to 4, Japanese encephalitis virus (JEV), and West Nile virus (WNV), and a vaccine strain of yellow fever virus (YFV) were used in the antiviral assays. Virus was amplified by passage in Vero cells (ATCC) cultured in minimum essential medium (MEM) supplemented with 1% fetal bovine serum (FBS, Gibco™, Life Technologies Corporation, Massachusetts, USA) and 100 units/ml penicillin plus 100 mg/ml streptomycin. Working stocks of virus were prepared at 4 x 106 tissue culture infectious
dose (TCID5o)/ml. For virus titration, aliquots of the working stock were applied on confluent Vero cells cultured in 96-well plates. Serial 10-fold dilutions of virus stock solution were inoculated (in quadruplicate) onto a Vero cell monolayer and subsequently cultured in penicillin/ streptomycin- supplemented MEM and 1% FBS. Wells of the plate were observed for cytopathic effect (CPE) for from 3 to 7 days. Viral titer was calculated using the Reed and Miinch endpoint method. One TCID50 was interpreted as the amount of virus that resulting in CPE in 50% of inoculated wells.
Drug compounds and cytotoxicity assay
[0032] Amantadine hydrochloride (Sigma-Aldrich Chemie GmbH, Steinheim, Germany), ciprofloxacin (Sigma-Aldrich Chemie GmbH), desmopressin acetate (Ferring Pharmaceuticals, Saint Prex, Switzerland), doxycycline hydrochloride (Sigma-Aldrich Chemie GmbH), isatin (Sigma-Aldrich Chemie GmbH), levodopa (Sigma-Aldrich Chemie GmbH), lopinavir-ritonavir (Abbott Laboratories, Illinois, USA), minocycline (Pfizer, New York City, USA), montelukast (Merck & Co., Inc., New Jersey, USA), novobiocin sodium (Sigma-Aldrich Chemie GmbH), octreotide acetate (Novartis, Basel, Switzerland), ribavirin (Sigma-Aldrich Chemie GmbH), rifampicin (Gruppo Lepetit Sri, Milan, Italy), selegiline (Sigma-Aldrich Chemie GmbH), sirolimus (Pfizer, New York city, USA), and tacrolimus (Astellas Pharma, Tokyo, Japan), were used in this study. The 50% effective cytotoxic concentration (CC50) of the selected drugs was characterized using a thiazolyl blue tetrazolium bromide (MTT) assay in accordance with the manufacturer's instructions.
CPE inhibition assay
[0033] For the CPE inhibition assay drug compounds were diluted with serum-free MEM and added to confluent Vero cells cultured in the wells of 96-well culture plates (4 x 104 cells/well) in triplicate, and incubated for 2 hours at 37° C. After incubation the drug-containing media were removed, and a flaviviridae virus (multiplicity of infection, MOI = 0.0001) was added to each well along with fresh drug-compound media. After an additional 1 hour at 37° C, the virus-drug compound mixture was removed and the cells were washed twice with MEM to remove unbound virus. Subsequently, drug-containing media were added to the cells for further incubation for 6 days at 37° C in 5% C02. CPE was determined by examination using inverted light microscopy,
and supernatant was collected for virus quantification. A 4: 1 mixture of serum free MEM and 5 mg/ml MTT solution (prepared in 1 x PBS, filtered) was then added to the wells. The cell monolayers were incubated as above for 4 hours in the absence of light. 10% sodium dodecyl sulfate with 0.01M HC1 was then added the wells, which were subsequently incubated at 37° C in 5% C02 overnight. Activity was characterized by measuring optical density at 570nm with reference absorbance read at 640nm. The half maximal inhibitory concentration (IC50) and CC50 were calculated using Sigma plot (SPSS) as Excel add-in ED50V10. Drug compounds were selected for combination studies with novobiocin or lopinavir-ritonavir using the CPE inhibition assay and the Loewe additivity index was calculated.
Virus yield reduction
[0034] Virus yield reduction was determined by quantitative reverse transcription-PCR (qRT- PCR) using total nucleic acid extracted from culture supernatants of the Vero cells infected by flaviviridae with different drugs or a dimethyl sulfoxide (DMSO) control at 6 days post- inoculation (dpi), β-actin gene was used as an internal control.
Plaque reduction
[0035] Plaque reduction (PRA) was determined by seeding Vero cells at 2 x 105 cells/well in 24- well tissue culture plates in MEM (Invitrogen, California, USA) with 10% FBS on the day prior to the assay. After 24 hours of incubation, 20-40 plaque-forming units of the virus were added to the cell monolayer with or without the addition of drug compounds and the plates further incubated for 1 hour at 37° C in 5% C02, after unbound viral particles were removed by aspiration of the media and washing with MEM. The monolayers were then overlaid with media containing 1% low melting agarose (Cambrex Corporation, New Jersey, USA) in MEM and appropriate concentrations of drug compounds and incubated as above for 96 hours. The wells were then fixed with 10% formaldehyde (BDH, Merck, Darmstadt, Germany) overnight.
Following removal of the agarose plugs the cell monolayers were stained with 0.7% crystal violet (BDH, Merck) and the plaques counted. The percentage of plaque inhibition relative to the control (without compound addition) plates was determined for each drug compound concentration. Experiments were performed in triplicate and repeated twice for confirmation.
[0036] Surprisingly, novobiocin and lopinavir-ritonavir exhibited antiviral activity against all tested viruses, including DENV serotypes 1 to 4, JEV, WNV, and YFV. The CC50 of novobiocin and lopinavir-ritonavir was 850.5 μg/ml (1,388.02μΜ) and 30.0 μg/ml in Vero cells,
respectively, and was l,103.18μg/ml (1,800.39μΜ) and 32.12μg/ml in Huh-7 cells, respectively. Virus yield reduction studies showed a dose-dependent reduction in virus titer in novobiocin- treated (IC50 = 26.12+0.33μg/ml or 42.63μΜ in Vero cells and 38.14+4.53μg/ml or 62.24μΜ in Huh-7 cells) and lopinavir-ritonavir-treated (IC50 = 4.78+0.4^g/ml in Vero cells and
3.31+0.36μg/ml in Huh-7 cells) cells. The mean virus titer was significantly reduced (P<0.05) at >25.0 μg/ml (40.8 μΜ) of novobiocin and at >50.0 μg/ml of lopinavir-ritonavir. Consistent with previous studies, amantadine, isatin, and levodopa exhibited antiviral activity against WNV, doxycycline and amantadine exhibited antiviral activity against DENV serotypes 1-4, and minocycline exhibited antiviral activity against JEV. Desmopressin, octreotide, rifampicin, selegiline, sirolimus, and tacrolimus did not exhibit apparent antiviral activity against any of the viruses.
[0037] Combination drug treatment studies of flavivirus -infected cells with novobiocin or lopinavir-ritonavir combined with secondary drugs such as amantadine, ciprofloxacin, doxycycline, isatin, levodopa, and/or ribavirin showed that such combinations provided an unexpected synergistic anti-flaviviral activity in vitro. Combination studies showed that the mean Loewe additivity indices of all of these combinations were <1.0, demonstrating that these drug combinations inhibited the in vitro replication of flaviviruses in a synergistic fashion.
[0038] It should be apparent to those skilled in the art that many more modifications besides those already described are possible without departing from the inventive concepts herein. The inventive subject matter, therefore, is not to be restricted except in the spirit of the appended claims. Moreover, in interpreting both the specification and the claims, all terms should be interpreted in the broadest possible manner consistent with the context. In particular, the terms "comprises" and "comprising" should be interpreted as referring to elements, components, or steps in a non-exclusive manner, indicating that the referenced elements, components, or steps may be present, or utilized, or combined with other elements, components, or steps that are not expressly referenced. Where the specification claims refers to at least one of something selected
from the group consisting of A, B, C .... and N, the text should be interpreted as requiring only one element from the group, not A plus N, or B plus N, etc.
Claims
1. A composition for the treatment of flaviviridae infection, comprising:
novobiocin; and
a secondary antiviral or antibiotic compound,
wherein the novobiocin and the secondary antiviral or antibiotic compound exhibit a synergistic effect in inhibiting a virus of the flavivirus family.
2. The composition of claim 1, wherein the secondary antiviral or antibiotic compound is selected from the group consisting of ribavarin, ritonavir, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, doxycycline, amantadine, levodopa, and isatin.
3. The composition of claim 1 or claim 2, wherein the virus of the flavivirus family is selected from the group consisting of dengue virus, Japanese encephalitis, West Nile virus, yellow fever virus, and hepatitis C virus.
4. The composition of one of claims 1 to 3, wherein the composition is formulated to provide novobiocin in a concentration range of about 1 μΜ to about 1 mM.
5. A composition for the treatment of flaviviridae infection, comprising:
lopinavir-ritonavir; and
a secondary antiviral or antibiotic compound,
wherein the novobiocin and the secondary antiviral or antibiotic compound exhibit a synergistic effect in inhibiting a virus of the flavivirus family.
6. The composition of claim 5, wherein the secondary antiviral or antibiotic compound is selected from the group consisting of ribavarin, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, and doxycycline, amantadine, levodopa, and isatin.
7. The composition of claim 5 or claim 6, wherein the virus of the flavivirus family is selected from the group consisting of dengue virus, Japanese encephalitis virus, West Nile virus, yellow fever virus, and hepatitis C virus.
8. The composition of one of claims 5 to 7, wherein the composition is formulated to provide lopinavir-ritonavir in a concentration range of about 1 μΜ to about 1 mM.
9. A method of treating an infection caused by a member of the flavivirus family, comprising providing, to a person in need of treatment, a formulation comprising novobiocin.
10. The method of claim 9, wherein the formulation further comprises a secondary antiviral or antibiotic compound.
11. The method of claim 10, wherein the secondary antiviral or antibiotic compound is selected from the group consisting of ribavarin, ritonavir, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, and doxycycline, amantadine, levodopa, and isatin.
12. The method of one of claims 9 to 11, wherein the formulation is configured to provide novobiocin in a concentration range of about 1 μΜ to about 1 mM.
13. The method of one of claims 9 to 12, wherein the member of the flavivirus family is selected from the group consisting of dengue virus, Japanese encephalitis virus, West Nile virus, yellow fever virus, and hepatitis C virus.
14. A method of treating an infection caused by a member of the flavivirus family, comprising providing, to a person in need of treatment, a formulation comprising lopinavir-ritonavir.
15. The method of claim 14, wherein the formulation further comprises a secondary antiviral or antibiotic compound.
16. The method of claim 15, wherein the secondary antiviral or antibiotic compound is selected from the group consisting of ribavarin, ritonavir, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, and doxycycline, amantadine, levodopa, and isatin.
17. The method of one of claims 14 to 16, wherein the formulation is configured to provide lopinavir-ritonavir in a concentration range of about 1 μΜ to about 1 mM.
18. The method of one of claims 14 to 17, wherein the member of the flavivirus family is selected from the group consisting of dengue virus, Japanese encephalitis virus, West Nile virus, yellow fever virus, and hepatitis C virus.
19. A kit for treating an infection caused by a member of the flavivirus family, comprising: novobiocin;
a secondary antiviral or antibiotic compound; and
instructions for use.
20. The kit of claim 19, wherein novobiocin and the secondary antiviral or antibiotic compound are provided as a single formulation.
21. The kit of claim 19, wherein novobiocin and the secondary antiviral or antibiotic compound are provided as separate formulations.
22. The kit of one of claims 19 to 21, wherein the secondary antiviral or antibiotic compound is selected from the group consisting of ribavarin, ritonavir, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, and doxycycline, amantadine, levodopa, and isatin.
23. The kit of one of claims 19 to 22, wherein the kit is configured to provide novobiocin in a concentration range of about 1 μΜ to about 1 mM.
24. The kit of one of claims 19 to 23, wherein the member of the flavivirus family is selected from the group consisting of dengue virus, Japanese encephalitis virus, West Nile virus, yellow fever virus, and hepatitis C virus.
25. The kit of one of claims 19 to 24, wherein instructions for use comprise a dosing schedule effective in treating the infection.
26. A kit for treating an infection caused by a member of the flavivirus family, comprising: lopinavir;
ritonavir;
a secondary antiviral or antibiotic compound; and
instructions for use.
27. The kit of claim 26, wherein lopinavir, ritonavir, and the secondary antiviral or antibiotic compound are provided as a single formulation.
28. The kit of claim 26, wherein lopinavir and ritonavir are provided as first formulation, and the secondary antiviral or antibiotic compound is provided as a second formulation.
29. The kit of claim 26, wherein lopinavir, ritonavir, and the secondary antiviral or antibiotic compound are provided as separate formulations.
30. The kit of one of claims 26 to 29, wherein the secondary antiviral or antibiotic compound is selected from the group consisting of ribavarin, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, and doxycycline, amantadine, levodopa, and isatin.
31. The kit of one of claims 26 to 30, wherein the kit is configured to provide lopinavir-ritonavir in a concentration range of about 1 μΜ to about 1 mM.
32. The kit of one of claims 26 to 31, wherein the member of the flavivirus family is selected from the group consisting of dengue virus, Japanese encephalitis virus, West Nile virus, yellow fever virus, and hepatitis C virus.
33. The kit of one of claims 26 to 32, wherein instructions for use comprise a dosing schedule effective in treating the infection.
34. Use of novobiocin for the manufacture of a medicament useful for treating an infection caused by a member of the flavivirus family.
35. The use of claim 34, wherein the medicament further comprises a secondary antiviral or antibiotic compound, and wherein novobiocin and the secondary antiviral or antibiotic compound provide a synergistic antiviral effect.
36. The use of claim 35, wherein the secondary antiviral or antibiotic compound is selected from the group consisting of ribavarin, ritonavir, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, and doxycycline, amantadine, levodopa, and isatin.
37. The use of one of claims 34 to 36, wherein the medicament is formulated to provide novobiocin in a concentration range of about 1 μΜ to about 1 mM.
38. The use of one of claims 34 to 37, wherein the member of the flavivirus family is selected from the group consisting of dengue virus, Japanese encephalitis virus, West Nile virus, yellow fever virus, and hepatitis C virus.
39. Use of lopinavir-ritonavir for the manufacture of a medicament useful for treating an infection caused by a member of the flavivirus family.
40. The use of claim 40, wherein the medicament further comprises a secondary antiviral or antibiotic compound, and wherein lopinavir-ritonavir and the secondary antiviral or antibiotic compound provide a synergistic antiviral effect.
41. The use of claim 40, wherein the secondary antiviral or antibiotic compound is selected from the group consisting of ribavarin, ritonavir, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, tigecycline, minocycline, and doxycycline, amantadine, levodopa, and isatin.
42. The use of one of claims 39 to 41, wherein the medicament is formulated to provide lopinavir-ritonavir in a concentration range of about 1 μΜ to about 1 mM.
43. The use of one of claims 39 to 42, wherein the member of the flavivirus family is selected from the group consisting of dengue virus, Japanese encephalitis virus, West Nile virus, yellow fever virus, and hepatitis C virus.
FIG. 3
19
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762521178P | 2017-06-16 | 2017-06-16 | |
US62/521,178 | 2017-06-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2018232174A2 true WO2018232174A2 (en) | 2018-12-20 |
WO2018232174A3 WO2018232174A3 (en) | 2019-01-24 |
Family
ID=64661021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/037629 WO2018232174A2 (en) | 2017-06-16 | 2018-06-14 | Compositions and methods for treating flavivirus infections |
Country Status (2)
Country | Link |
---|---|
TW (1) | TW201904585A (en) |
WO (1) | WO2018232174A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3909578A1 (en) * | 2020-05-12 | 2021-11-17 | Universidad de Castilla la Mancha | Antiviral composition comprising eeyarestatin i |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2665370A1 (en) * | 2005-10-03 | 2007-04-12 | University Health Network | Odcase inhibitors for the treatment of malaria |
JP2013522375A (en) * | 2010-03-24 | 2013-06-13 | バーテックス ファーマシューティカルズ インコーポレイテッド | Analogs for treating or preventing flavivirus infection |
AR091279A1 (en) * | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | MACROCICLIC INHIBITORS OF VIRUS FLAVIVIRIDAE |
-
2018
- 2018-06-14 WO PCT/US2018/037629 patent/WO2018232174A2/en active Application Filing
- 2018-06-15 TW TW107120851A patent/TW201904585A/en unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3909578A1 (en) * | 2020-05-12 | 2021-11-17 | Universidad de Castilla la Mancha | Antiviral composition comprising eeyarestatin i |
WO2021228714A1 (en) * | 2020-05-12 | 2021-11-18 | Universidad De Castilla La Mancha | Antiviral composition comprising eeyarestatin i |
Also Published As
Publication number | Publication date |
---|---|
WO2018232174A3 (en) | 2019-01-24 |
TW201904585A (en) | 2019-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101706624B1 (en) | Agent for the prophylaxis and treatment of highly pathogenic infectious diseases | |
AU2005237208B2 (en) | Treatment of infectious diseases | |
ES2810303T3 (en) | Thiazolid compounds to treat viral infections | |
KR20190071765A (en) | Antiviral compositions for the treatment of infections associated with coronaviruses | |
Wang et al. | Artemisinin inhibits the replication of flaviviruses by promoting the type I interferon production | |
US20090304630A1 (en) | Treating severe and acute viral infections | |
WO2018232174A2 (en) | Compositions and methods for treating flavivirus infections | |
BR112022019198A2 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF EPIDEMIC RIBONUCLEIC ACID VIRUS INFECTIONS, AND, USE OF A THERAPEUTICLY EFFECTIVE AMOUNT OF PIRONARIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ARTEMISININ OR A DERIVATIVE THEREOF | |
CN114786659A (en) | MEK inhibitors for the treatment of hantavirus infection | |
WO2017223178A1 (en) | Treating viral infections with impdh inhibitors | |
CN114762694B (en) | Use of oligosaccharide transferase inhibitors for the prevention and/or treatment of novel coronavirus infections | |
Lee et al. | Antiviral effect of vesatolimod (GS-9620) against foot-and-mouth disease virus both in vitro and in vivo | |
US3980774A (en) | Method of viral chemoprophylaxis and compounds therefor | |
US20230241037A1 (en) | Cross-linked medication for treatment of coronaviral infection and method of treatment | |
US20070212426A1 (en) | Composition and method of retarding viral activity and reducing viral replication | |
US20140148447A1 (en) | Agent for prophylactic and therapeutic treatment of herpes infections | |
US4032659A (en) | Method of viral chemoprophylaxis | |
US20230398090A1 (en) | Method of treating coronavirus infection by administration of ethyl mercury or thiol derivative thereof | |
WO2019185579A1 (en) | Use of quercetin-3-o-glucoside for the treatment of flavivirus infections | |
EP3892268A1 (en) | Use of vidofludimus for the treatment of coronavirus infections | |
US20060280723A1 (en) | Interferon for treating or preventing a coronaviral infection | |
US20220273641A1 (en) | Method for treating coronavirus infections including SARS-CoV-2 | |
WO2008097112B1 (en) | Amidinoanthracycline antibiotics for use in the treatment of viral infections | |
WO2017202789A1 (en) | Methods and pharmaceutical compositions for the treatment of filovirus infections | |
AU2017210921B2 (en) | Composition and combined medication method for treating enterovirus infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18817639 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18817639 Country of ref document: EP Kind code of ref document: A2 |